Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linezolid versus vancomycin/oxacillin/dicloxacillin for catheter-related gram-positive bloodstream infections
2004-001511-54Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2004
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of linezolid, vancomycin, Oxacillin and dicloxacillin in catheter-associated bloodstream infection (CRBSI) (2 arms), sponsored by Pfizer. Primary endpoint: Primary microbiological outcome at short-term follow-up. Started Sep 2004; status: completed.
02
Drugs
linezolidvancomycinOxacillindicloxacillin
03
Conditions
catheter-associated bloodstream infection (CRBSI)
Beyond the preview
Go deeper on 2004-001511-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001511-54.